Vascular endothelial growth factor antagonist reduces the early onset and the severity of ovarian hyperstimulation syndrome

Huang

Cell Biology International

et al. 2019

Vascular endothelial growth factor (VEGF) plays an essential role in luteal angiogenesis, the present study therefore utilized luteal cells cultured in vitro to further investigate the activation and contribution of nuclear factor (NF)‐κB to VEGF expression induced by human chorionic gonadotrophin (HCG). The present results showed HCG induced VEGF expression as well as hypoxia‐inducible factor (HIF)‐1α mRNA and protein expressions, which was blocked by NF‐κB inhibitor pyrrolidine dithiocarbamate (PDTC). Further analysis found that these increases of VEGF and HIF‐1α mRNA induced by HCG were also blocked by NF‐κB siRNA transfection, which was consistent with PDTC treatment. However, HIF‐1α siRNA treatment significantly decreased HCG induced‐VEGF expression with no effect on NF‐κB mRNA expression. Furthermore, combination of HIF‐1α siRNA and PDTC treatment did not further decrease VEGF mRNA expression, and the result of chromatin immunoprecipitation indicated NF‐κB may regulate HIF‐1α transcription through binding with its promoter. Taken together, the present results clearly demonstrated that NF‐κB was activated to regulate VEGF expression by increasing HIF‐1α transcription in luteal cells treated with HCG. Therefore, the present study provided a new and important mechanism of luteal angiogenesis during the formation of corpus luteum in mammals.

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Activation of NF‐κB signaling pathway during HCG‐induced VEGF expression in luteal cells

Huang

Cell Biology International

et al. 2019

“…-460 C/T and +405 G/C gene polymorphisms enable increase permeability and the mechanism of OHSS is increased capillary permeability, therefore, OHSS could be reduced using VEGF antagonist (16). Nouri and colloquies confirmed that VEGF gene polymorphism is related with the happening of OHSS (13).…”

Section: Discussionmentioning

confidence: 99%

Association of -460C/T and +405 G/C polymorphisms of vascular endothelial growth factor gene and susceptibility of ovarian hyperstimulation syndrome

Ghasemi

Firouzabadi

Ahmadi

2017

IJRM

Background:Ovarian hyperstimulation syndrome (OHSS) is one of the most important complications of assisted reproduction treatment. Many substances are involved in the regulation of the vascular permeability, which have been concerned to cause OHSS. Vascular endothelial growth factor (VEGF) has emerged as one of the main angiogenic factors, which could be responsible for increased vascular permeability.Objective: In this study the association of vascular endothelial growth factor -460C/T and +405 G/C polymorphisms and susceptibility to ovarian hyperstimulation syndrome was evaluated. Materials and Methods:In this cross sectional study, VEGF gene polymorphisms were amplified by Polymerase chain reaction- Restriction Fragment Length Polymorphism in 75 women with established OHSS (case group) and 85 normoresponder (control group) which received conventional ovarian stimulation regimen. Results:There was no significant difference in the frequency of -460 C/T polymorphism between cases and controls (p=0.85). The frequency of +405 G/C polymorphism was significantly higher in the OHSS women (p=0.03, OR=2.44; 95% CI=1.23-4.82). Conclusion: In women who developed OHSS, VEGF gene polymorphism +405 could be effective. Two of the polymorphisms -460 C/T and +405 G/C were reported to be associated with increased VEGF basal promoter activity. However, only +405 G/C gene polymorphisms were more frequent in cases than controls.

“…To prevent OHSS, we have cancelled induction cycles, discontinued gonadotropin therapy (coasting), decreased the dosage of the hCG trigger, used an agonist trigger, and used embryo cryopreservation. Recently, the use of a vascular endothelial growth factor antagonist has been considered to reduce the early onset and severity of OHSS [10,11].…”

Section: Discussionmentioning

confidence: 99%

Ovarian Hyperstimulation Syndrome Due to Exogenous Human Chorionic Gonadotropin (hCG) Presenting More Than 7 Days After hCG Administration

Kobayashi¹,

Kumasawa²,

Koizumi³

et al. 2017

JGO

Abstract:We present a case of ovarian hyperstimulation syndrome (OHSS) occurring 8 days after human chorionic gonadotropin (hCG) administration. OHSS is classified as late type if it occurs 12 to 17 days after hCG administration and early type if it occurs within 7 days. Thus, the condition in this patient did not fit the definition of early or late OHSS. The OHSS was mild, and she recovered in approximately 10 days without requiring admission. The patient was not pregnant, and the OHSS was shown to be induced by exogenous hCG administration not endogenous hCG. In conclusion, OHSS can occur 8 to 11 days after hCG administration and it is important to distinguish whether OHSS is induced by endogenous or exogenous hCG.